
Lemborexant 10 mg, a dual orexin-receptor antagonist, demonstrated respiratory safety in moderate-to-severe COPD patients, with no adverse impact on oxygen saturation (SpO2) or apnea–hypopnea index. The study found improved sleep parameters with lemborexant versus placebo, with mild side effects. As the first DORA to confirm respiratory safety in severe COPD, lemborexant offers a potential treatment for insomnia in these patients.
Like
Save
Share